Lipid Panel, Cardio IQ®
Test Code
91716
80061
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
Clinical Significance
Lipid Panel, Cardio IQ® - This is the most common Lipid Panel. Components include those useful in the detection, classification, and monitoring of patients with hyperlipidemia.
Test Resources
Test FAQ
LDL Cholesterol CalculationsTest Summary
Cardiometabolic Disease Assessment (CMDA) PanelTest Summary
LDL CholesterolTest Summary
Metabolic Risk PanelTest Details
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Fasting is not required prior to collection of a lipid panel.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been. . . determined to interfere with assays for. . . cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hrs and a third dose of 100 mg/kg administered over 16 hrs.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been. . . determined to interfere with assays for. . . cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hrs and a third dose of 100 mg/kg administered over 16 hrs.
Methodology
Spectrophotometry (SP)
Reference Range(s)
| Total Cholesterol | Male (mg/dL) | Female (mg/dL) |
| <20 Years | <170 | <170 |
| ≥20 Years | <200 | <200 |
| HDL Cholesterol | ||
| <20 Years | >45 | >45 |
| ≥20 Years | ≥40 | ≥50 |
| Triglycerides | ||
| ≤9 Years | <75 | <75 |
| 10-19 Years | <90 | <90 |
| ≥20 Years | <150 | <150 |
| LDL-Cholesterol | |
| <20 Years | <110 mg/dL (calc) |
| ≥20 Years | <100 mg/dL (calc) |
| Cholesterol/HDL Ratio | <5.0 calc |
| Non-HDL Cholesterol | |
| <20 Years | <120 mg/dL (calc) |
| ≥20 Years | <130 mg/dL (calc) |
Alternative Name(s)
CardioIQ®,Cardio IQ® Lipid Panel
Preferred Specimen(s)
1 mL serum
Minimum Volume
0.5 mL
Transport Container
Transport tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 48 hours
- Refrigerated: 7 days
- Frozen: 28 days
Reject Criteria
Gross hemolysis • Moderate to gross icterus • Anticoagulants other than heparin
Setup Schedule
1 mL serum
0.5 mL
Transport tube
Refrigerated (cold packs)
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 28 days
Refrigerated: 7 days
Frozen: 28 days
Gross hemolysis • Moderate to gross icterus • Anticoagulants other than heparin